Trial intelligence / Profile preview

Ranolazine Added to Metformin in Type 2 Diabetes

NCT01555164Phase 3Completed

Sponsor
Gilead Sciences
Start
Jun 2012
Primary completion
Sep 2013
Modality
Small Molecules
Countries
11
01

Overview

A Phase 3 trial of ranolazine in type 2 diabetes mellitus (T2DM), sponsored by Gilead Sciences. Started Jun 2012; status: completed.

02

Drugs

ranolazine
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT01555164.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01555164.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call